Tempest Therapeutics, Inc. (TPST) Financials

TPST Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 10.7 million 9.9 million
Dec. 31, 2025 16.9 million 10.3 million
Sept. 30, 2025 17.1 million 10.8 million
June 30, 2025 24.5 million 14.7 million

TPST Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -7.6 million 226000
Dec. 31, 2025 -3.6 million 576000
Sept. 30, 2025 -6.8 million 61000
June 30, 2025 -8.4 million 1.1 million

TPST Net Income

No data available :(

TPST Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 1.8 million 6.6 million -
Dec. 31, 2025 7.7 million 6.9 million 8.1 million
Sept. 30, 2025 7.5 million - 8.4 million
June 30, 2025 14.3 million - 8.7 million

TPST Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 10.9 million
Dec. 31, 2025 4.1 million
Sept. 30, 2025 4.4 million
June 30, 2025 3.8 million

TPST Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 114000 5.4 million -
Dec. 31, 2025 - 538000 3.5 million -
Sept. 30, 2025 - 570000 3.0 million -
June 30, 2025 - 3.9 million 4.1 million -

TPST Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 22.2 million
Dec. 31, 2025 - 65000
Sept. 30, 2025 - 66000
June 30, 2025 - 67000

TPST

Price: $1.23

52 week price:
1.23
12.23

Earnings Per Share: -5.70 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 5600

Market Capitalization: 5.6 million

Links: